This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Prognosis

Authoring team

Early-onset scoliosis is a heterogeneous constellation of diseases. Prognosis is linked largely to the co-morbidities and deformity at the time of presentation.

During the first 2 years, lung development is significant. By year 8, alveolar maturation will level off. Those with limited thoracic function due to scoliosis development can see alveolar hypoplasia, abnormal ventilation, and decreased lung compliance. Cardiac issues such as cor pulmonale and pulmonary hypertension can also present. The inability of the thoracic to appropriately lung growth and function are known as thoracic insufficiency syndrome.

Prognosis of the deformity is related heavily to the skeletal maturity of the patient as well as a degree of deformity. Thoracic to sacral spine grows at approximately 2 cm per year for the first 5 years of life and then 1 cm per year from ages 5 to 10 with 1.8 cm per year until maturity. Rapid growth is seen in the first 5 years and then during the adolescent phase.

The rib-vertebral angle (RVAD) at the apical vertebrae is prognostic for the progression of early-onset scoliosis from idiopathic conditions. An RVAD of greater than 20 degrees an initial presentation is more likely to progress.

Reference

  1. LeFever D, Menger RP. Infantile and Juvenile Scoliosis. StatPearls [Internet] January 2020

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2026 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.